FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades of industry leadership experience, including early- and late-stage therapeutic development and commercialization. "I am delighted to welcome Mitch and Angie to the team. They are industry leaders with a proven trac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 20-8969493 (State or other j ...

Exhibit 99.1 Alpine Immune Sciences Reports First Quarter 2024 Financial Results SEATTLE, Washington - May 9, 2024 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine announced that the companies had entered into a definitive ...

Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio. The broader biotech industry is brimming with significant potential, making incredible advancements. Innovations span fields like drug discovery, gene editing, regenerative medicine and diagnostics. These technologies hold promise to treat a wide range of dis ...

Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (ALPN -0.05%) from Vertex Pharmaceuticals (VRTX -0.92%). Vertex recently offered Alpine Immune Sciences $65 per share, or about $4.9 billion in cash. On April 9, the day before the announcement, Alpine's stock price closed at about $39 per share ...

Alpine Immune Sciences (ALPN) signed a definitive agreement with Vertex Pharmaceuticals (VRTX) . Per the terms, the pharma giant will acquire all outstanding shares of Alpine for $65 per share in cash, aggregating to $4.9 billion. A clinical-stage pharmaceutical company, Alpine is engaged in the development of multi-functional therapies targeting both autoimmune and inflammatory diseases. The acquisition will also include Alpine’s lead asset, povetacicept (formerly ALPN-303), designed to target two proteins ...

NEW YORK, April 11, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: Alpine Immune Sciences, Inc. has agreed to be ...

The Nasdaq is leading the charge today, with biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) up over 2% today. Digging deeper, Alpine Immune Sciences Inc (NASDAQ:ALPN) is soaring to eight- year highs today, up 36.9% to trade at $64.39, after news that Vertex Pharmaceuticals (VRTX) will acquire the biotech company for $4.9 billion. The buyout represents a 67% premium to ALP's share price before rumors of it. The news is lifting Vera Therapeutics Inc (NASDAQ:VERA) as well, as Vera's lead candida ...

Drug maker Alpine Immune Sciences (NASDAQ:ALPN) got a $4.9 billion buyout offer from Vertex Pharmaceuticals (NASDAQ:VRTX) after getting good news on a new drug. Povetacicept, an autoimmune drug, won a successful Phase 2 review from the Food and Drug Administration (FDA) for treating a rare kidney disease and will go into Phase 3 trial. Alpine stock rose 21% on April 10, and another 36% overnight, opening April 11 at $64.18 per share. More Than Kidneys? While Povetacicept is only being tested for a rare kidn ...

Alpine Immune Sciences Inc 股价上涨 - Alpine Immune Sciences Inc (NASDAQ: ALPN) 股价上涨35%，因为 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) 宣布将以每股65美元的价格收购这家生物技术公司[1] - Alpine Immune 股价今年迄今已经增长了三倍以上[4] 调查展开 - Halper Sadeh LLC 对 Alpine Immune 和 Vertex 达成的协议展开调查，可能会寻求提高收购价格或其他补偿措施[2] 合作展望 - Alpine Immune Sciences 的首席执行官 Mitchell H. Gold 相信与 Vertex Pharmaceuticals 合作将有助于公司在全球患者生活中产生重大影响[7] 交易预期 - Vertex 预计这笔全现金交易将有助于扩大其在肾脏疾病治疗领域的业务范围，预计将在本季度结束前完成[8] 评级下调 - 摩根士丹利的分析师将 Alpine Immune 股票评级下调为“持平”，价格目标为65美元，与当前股价大致相符[9]